

"Press release"

Results for the year ended December 31, 2009: 3.1% revenue growth Net profit decline Reduction in net debt achieved through asset disposals

Paris, February 11, 2010

- **Revenue**: + 3.1% growth, including + 3.6% organic growth.
- > Current operating profit: + 1.1% growth

Efforts to keep expenses under control in 2009 have limited the reduction in the current operating margin (5.7% in 2009 vs 5.8% in 2008), attributable to:

- an unfavorable scissor effect on prices,
- higher rent and depreciation expenses, as a result of the sustained investment policy pursued over the last few years.

€m	2009	Change	2008
Revenue	2,046.2	+ 3.1%	1,983.8
EBITDA	237.0	+ 3.2%	229.6
Current operating profit	116.1	+ 1.1%	114.8
As % of revenue	5.7%	- 0.1 point	5.8%
Operating profit	131.4	- 18.1%	160.4
Group share of net profit	42.4	- 51.4%	87.2
Net earnings per share (€)	0.76	- 52.2%	1.59

Revenue – Consolidated revenue for the year ended December 31, 2009 amounted to €2,046.2m

compared to €1,983.8m one year earlier.

€m	2009	2008	Change 2009/2008	Q4 2009	Q4 2008	Change 2009/2008
lle de France	769.2	749.2	+ 2.7%	202.8	196.8	+ 3.0%
Rhône Alpes	313.7	263.0	+ 19.3%	83.3	77.3	+ 7.8%
Nord	213.7	207.1	+ 3.2%	55.0	54.0	+ 1.9%
Provence Alpes Côte d'Azur	232.7	226.9	+ 2.6%	59.4	56.6	+ 4.9%
Other French regions	447.7	445.5	+ 0.5%	115.7	114.9	+ 0.7%
Italy	69.2	92.1	- 24.9%	19.3	18.1	+ 6.6%
Published revenue	2,046.2	1,983.8	+ 3.1%	535.5	517.7	+ 3.4%
o/w: - Organic	1,988.5	1,918.5	+ 3.6%	533.2	504.1	+ 5.8%
o/w organic France	1,919.3	1,852.1	+ 3.6%	513.9	486.2	+ 5.7%
o/w organic Italy	69.2	66.4	+ 4.2%	19.3	17.9	+ 7.8%
- Changes in scope	57.7	65.3	-	2.3	13.6	-

In the fourth quarter of 2009, Hospital Care France recorded +5.7% organic growth, which breaks down as follows:

- a + 0.5% price effect
- a + 5.2% volume/mix effect (including a favorable base effect compared with the fourth quarter of 2008 which was impacted by the economic slowdown).

The main changes in the scope of consolidation relate to the acquisition of Clinique de Saint Victor (mental health) near Saint-Etienne in the second quarter of 2009, Clinique de la Francilienne and Clinique de l'Orangerie in the eastern Paris region as well as Centre Hospitalier Privé de la Loire (Saint-Etienne) in September 2008; combined with a number of disposals, particularly Clinique Hartmann (Neuilly) in March 2009 and Parc Saint Lazare (Beauvais) in April 2009.

The other divestments (Biology unit in Italy; homecare, two dialysis centers and Clinique Tourny in Bordeaux) were carried out at the end of the year.

Overall, given the changes in consolidation scope, Hospital Care France grew +3.3% in Q4 2009.

In Q4 2009, revenue generated in Italy achieved organic growth of +7.8%.

Results – The decline in operating profit from €160.4m to €131.4m was mainly attributable to the change in non-recurring items between 2008 and 2009:

- in 2008, a net capital gain of €70m was recorded following the divestment of the buildings of four clinics in the Paris region and of certain Italian subsidiaries,
- in 2009, the net capital gain was €21m on the disposals disclosed above.

Debt management and a reduction in interest rates in 2009 significantly reduced the cost of debt, which fell from €72.5m to €55.3m, representing a €17.2m reduction (almost -24% vs 2008).

Moreover, corporate income tax increased by €31.6m, mainly as a result of the change in deferred tax between 2008 (positive impact from the disposal of Vesta) and 2009 (consequence of the application under the French finance law, adopted as of December 30, 2009, of the Business Value-Added Contribution (CVAE), leading to the recognition of a net deferred tax expense of €8.6m in accordance with IAS 12).

Net profit (group share) fell from €87.2m in 2008 to €42.4m in 2009.

Debt – Net financial debt per IFRS was €885.8m at end-December 2009 (compared to €913.0m at end-December 2008). This reduction was due notably to the disposals of the Homecare unit (France) and Biology unit (Italy) in December. However, the extent of the reduction was lessened by an adverse impact of some €60m as a result of measures introduced under the French Law on the Modernization of the Economy (LME).

Post balance sheet event – On February 2nd, 2010, the group finalized the disposal of its French diagnostics activities (medical analysis laboratories representing 2009 revenue of around €60m) as part of a strategy to focus its activity on Hospital Care in France initiated in 2008, which continued into 2009.

Dates for your diary:

Publication of first quarter 2010 accounts: April 22, 2010 Annual Shareholders' Meeting: May 31, 2010

Générale de Santé, listed on Compartment A of Eurolist by Euronext Paris (formerly known as the Premier Marché) since June 2001, is included in the Midcac index. Its shares are eligible for the deferred settlement service. As the leading Group in the private hospital care sector in France, Générale de Santé has 21,500 employees, including 7,000 nurses and 4,100 assistant nurses in 110 hospitals and clinics. With 5,500 physicians, it represents the leading independent medical community in France. Générale de Santé provides a complete range of patient care services spanning: acute care, oncology, subacute care and rehabilitation, mental health and homecare. Générale de Santé develops an original healthcare offering, combining medical excellence, organizational efficiency and a human touch; it provides an all-in-one service with an individually-adapted patient support package, before, during and after hospitalization, taking into consideration all of its patients' needs; it takes part in public-service healthcare initiatives and forms part of the nationwide healthcare chain in France.

ISIN and Euronext Paris: FR0000044471 Internet: <u>www.generale-de-sante.fr</u>

Investor Relations/Analysts: Emmanuel de Geuser Tel. + 33 (0)1 53 23 14 89 e.degeuser@gsante.fr Press Relations: Gérard Benedetti Tel. + 33 (0) 1 53 23 14 47 g.benedetti@gsante.fr

STATEMENT OF COMPREHENSIVE INCOME

INCOME STATEMENT (in million euros)	2007	2008	2009
TURNOVER	1 906.0	1,983.8	2,046.2
Personnel expenses and profit sharing	(844.0)	(894.1)	(926.7)
Purchased consumables	(372.8)	(396.6)	(394.1)
Other operating income and expenses	(234.3)	(238.6)	(247.3)
Taxes and duties	(104.0)	(107.6)	(106.4)
Rents	(111.7)	(117.3)	(134.7)
EBITDA	239.2	229.6	237.0
Depreciation	(107.8)	(114.8)	(120.9)
Current operating profit	131.4	114.8	116.1
Restructuring costs	(25.6)	(20.0)	(13.7)
Result of the management of real estate and financial assets	1.0	65.6	29.0
Impairment of goodwill			
Other non current income and expenses	(24.6)	45.6	15.3
Operating profit	106.8	160.4	131.4
Gross interest expenses	(31.4)	(74.8)	(56.4)
Income from cash and cash equivalents	1.4	2.3	1.1
Net interest expenses	(30.0)	(72.5)	(55.3)
Other financial income	5.4	2.3	0.6
Other financial expenses	(4.0)	(5.2)	(4.9)
Other financial income and expenses	1.4	(2.9)	(4.3)
Corporate income tax	(29.7)	5.1	(26.5)
Share of net profit of associates			
NET PROFIT FOR THE PERIOD	48.5	90.1	45.3
Revenues and expenses recognised directly as equity			
- Retirement commitments	(10.2)	2.5	1.7
- Change in fair value of hedging financial instruments	1.5	(23.2)	(2.6)
- Translation differential	(0.1)	(0.2)	
- Income tax on other comprehensive income	3.5	6.6	0.3
Résults recognised directly as equity	(5.3)	(14.3)	(0.6)
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	43.2	75.8	44.7
PROFIT ATTRIBUTABLE TO (in million euros)	2007	2008	2009
Group's share of net earnings	45.6	87.2	42.4
Minority interests	2.9	2.9	2.9
NET PROFIT FOR THE PERIOD	48.5	90.1	45.3
NET EARNINGS PER SHARE (in euros)	0.84	1.59	0.76
NET DILUTED EARNINGS PER SHARE (in euros)	0.82	1.59	0.76
TOTAL COMPREHENSIVE INCOME ATTRIBUTABLE TO (in millions euros)	2007	2008	2009
Group's comprehensive income for the period	40.3	72.9	41.8
Minority interests	2.9	2.9	2.9
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	43.2	75.8	44.7

CONSOLIDATED BALANCE SHEET - ASSETS

(in million euros)	12-31-2007	12-31-2008	12-31-2009
Goodwill	648.6	723.4	627.9
Other intangible fixed assets	7.3	15.9	19.2
Tangible fixed assets	960.7	962.5	915.6
Investments in associates	1.3	0.9	0.1
Other long-term investments	33.0	32.1	28.1
Deferred tax assets	34.8	54.6	50.5
NON CURRENT ASSETS	1,685.7	1,789.4	1,641.4
Inventories	35.0	38.4	32.8
Trade and other receivables	179.9	174.8	130.0
Other current assets	94.8	124.4	139.9
Current tax assets	11.6	2.8	2.0
Current financial assets	4.9	3.2	13.2
Cash and cash equivalents			
Assets held for sale	84.8	3.1	56.2
CURRENT ASSETS	411.0	346.7	374.1
TOTAL ASSETS	2,096.7	2,136.1	2,015.5

CONSOLIDATED BALANCE SHEET – LIABILITIES

(in million euros)	12-31-2007	12-31-2008	12-31-2009
Share capital	41.1	42.2	42.2
Additional paid-in capital	50.8	61.5	62.5
Consolidated reserves	304.9	309.5	320.0
Group's share of net profit	45.6	87.2	42.4
Group's share of equity	442.4	500.4	467.1
Minority interests	9.6	10.0	10.0
TOTAL SHAREHOLDERS' EQUITY	452.0	510.4	477.1
Borrowings and financial debts	871.4	847.1	812.4
Provisions for retirement and other employee benefits	29.5	29.6	29.7
Non-current provisions	26.0	39.5	37.3
Other long term liabilities	16.3	36.3	35.4
Deferred tax liabilities	84.4	72.2	81.3
NON CURRENT LIABILITIES	1,027.6	1,024.7	996.1
Current provisions	21.2	17.8	13.8
Accounts payable	166.6	196.4	124.1
Other current liabilities	270.2	305.4	296.2
Tax liabilities due	3.5	26.5	0.6
Short-term borrowings	47.8	45.0	44.7
Bank overdraft	35.5	6.8	5.1
Liabilities related to assets held for sale	72.3	3.1	57.8
CURRENT LIABILITIES	617.1	601.0	542.3
TOTAL EQUITY AND LIABILITIES	2,096.7	2,136.1	2,015.5

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

(in million euros)	SHARE CAPITAL	ADDITION AL PAID IN CAPITAL	RESERVES		TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	GROUP'S SHARE OF EQUITY	MINORITY INTERESTS	SHAREHOL DERS' EQUITY
Shareholders' equity at 31 december 2006	40.2	446.8	101.5	-	225.4	813.9	8.6	822.5
Capital increase (including net fees)	0.8	24.9		_		25.7		25.7
Treasury shares			0.3		-	0.3		0.3
Stocks options and free share			1.1		-	1.1		1.1
Prior year appropriation of earnings		(1.1)	226.5		(225.4)			-
Distribution of dividends			(19.2)		-	(19.2)	(1.9)	(21.1)
Exceptional distribution of additional paid-in capital		(419.8)			-	(419.8)		(419.8)
Change in consolidation scope					-			-
Total comprehensive income for the period					45.6	45.6	2.9	48.5
Profit and loss directly recognised against equity	0.1			(5.3)	-	(5.2)	-	(5.2)
Shareholders' equity at 31 december 2007	41.1	50.8	310.2	(5.3)	45.6	442.4	9.6	452.0
Capital increase (including net fees)	1.1	10.7		_		11.8		11.8
Treasury shares			(0.6)		-	(0.6)		(0.6)
Stocks options and free share			1.3		-	1.3		1.3
Prior year appropriation of earnings			45.6		(45.6)	-		-
Distribution of dividends			(27.4)		-	(27.4)	(2.7)	(30.1)
Change in consolidation scope					-		0.2	0.2
Total comprehensive income for the period				(14.3)	87.2	72.9	2.9	75.8
Shareholders' equity at 31 december 2008	42.2	61.5	329.1	(19.6)	87.2	500.4	10.0	510.4
Capital increase (including net fees)		1.0			-	1.0		1.0
Treasury shares			(9.4)		-	(9.4)		(9.4)
Stocks options and free share			2.6		-	2.6		2.6
Prior year appropriation of earnings			87.2		(87.2)			
Distribution of dividends			(69.3)			(69.3)	(1.8)	(71.1)
Change in consolidation scope							(1.1)	(1.1)
Total comprehensive income for the period				(0.6)	42.4	41.8	2.9	44.7
Shareholders' equity at 31 december 2009	42.2	62.5	340.2	(20.2)	42.4	467.1	10.0	477.1
	12-31-2007	12-31-2008	12-31-2009					
Dividends per share (in euros including pre-distribution)	8.02	0.5	1.23					
Number of treasury shares		53 346	773 668					

REVENUES AND EXPENSES RECOGNISED DIRECTLY AS EQUITY

(in million euros)	12-31-2007	Revenues and expenses 2008	12-31-2008	Revenues and expenses 2009	12-31-2009
Translation differential	(0.1)	(0.2)	(0.3)		(0.3)
Retirement commitments	(6.7)	1.6	(5.1)	1.1	(4.0)
Fair value of hedging financial instruments	1.5	(15.7)	(14.2)	(1.7)	(15.9)
Results recognised directly as equity (Group's share)	(5.3)	(14.3)	(19.6)	(0.6)	(20.2)

CONSOLIDATED CASH FLOW STATEMENT

(in million euros)	2008	2008	2009
Total net consolidated profit	48.5	90.1	45.3
Depreciation	107.8	114.8	120.9
Other non current income and expenses	24.6	(45.6)	(15.3)
Share of net profit of associates			
Other financial income and expenses	(1.4)	2.9	4.3
Net interest expenses	30.0	72.5	55.3
Corporate income tax	29.7	(5.1)	26.5
EBITDA	239.2	229.6	237.0
Non cash items including provisions and reversals (transactions with no cash effect)	(1.4)	3.5	(2.9)
Other income and expenses paid	(18.3)	(9.7)	(9.5)
Changes in other long term assets and liabilities	1.7	(5.2)	(2.5)
Cash flow before net interest expenses & taxes	221.2	218.2	222.1
Corporate income tax paid	(41.7)	(4.1)	(34.8)
Change in working capital requirements	0.1	39.2	(38.3)
NET CASH FROM OPERATING ACTIVITIES : (A)	179.6	253.3	149.0
Purchase of property, plant & equipment and intangible assets	(163.3)	(131.7)	(103.9)
Proceeds from sale of tangible and intangible assets	3.0	177.1	28.9
Purchase of financial assets	(102.3)	(58.9)	(25.3)
Proceeds from the disposal of financial assets	0.6	52.5	125.7
Dividends from non consolidated companies	0.8	1.0	0.6
NET CASH USED FOR INVESTING ACTIVITIES : (B)	(261.2)	40.0	26.0
Capital increase: (a)	25.7	11.8	1.0
Capital increase performed by subsidiaries subscribed to by third parties (b)			
Exceptional distribution of additional paid-in capital (c)	(419.8)		
Dividends paid to GDS shareholders: (d)	(19.2)	(27.4)	(69.3)
Dividends paid to minority interests of consolidated companies: (e)	(1.9)	(2.7)	(1.8)
Net interest expense paid : (f)	(30.0)	(72.5)	(55.3)
Debt issue costs : (g)	(25.0)	(1.1)	
Cash flow before repayment of borrowings: (h) = (A+B + a + b + c + d + e + f + g)	(551.8)	201.4	49.6
Increase in borrowings : (i)	857.8	103.4	140.2
Repayment of borrowings : (j)	(279.9)	(276.1)	(175.1)
NET CASH USED FOR FINANCING ACTIVITIES: (C) = a + b + c + d + e + f + g + i + j	107.7	(264.6)	(160.3)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS: (A + B + C)	26.1	28.7	14.7
Reclassification of the cash of the assets held for sale			(13.0)
Cash and cash equivalents at beginning of period	(61.6)	(35.5)	(6.8)
Cash and cash equivalents at end of period	(35.5)	(6.8)	(5.1)
Net indebtedness at beginning of period	439.0	1,001.3	913.0
Cash flow before repayment of borrowings: (h)	551.8	(201.4)	(49.6)
Capitalization of financial leases	23.3	33.9	31.0
Loan issue charges fixed assets	(24.4)	3.5	3.5
Assets held for sale	(7.7)	(9.2)	1.7
Fair value of financial hedging instruments	(1.5)	15.7	1.7
Change in scope of consolidation and other	20.8	69.2	(15.5)
Net indebtedness at end of period	1,001.3	913.0	885.8